Maxim Merchant Capital
300 Park Ave 16th Floor, New York, NY, 10022, United States
Overview
Maxim Group is an investment banking, securities, and investment management firm. The Firm provides an array of financial services including investment banking, equity research, private wealth management, structured products, and global institutional equity, fixed-income, and derivative sales & trading to a diverse range of corporate clients, institutional investors, and high-net-worth individuals. Maxim Group is registered as a broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); International Securities Exchange (ISE); NASDAQ Stock Market; and NYSE Arca, Inc.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 9
Sector focus
- Financial Services
- FinTech
- Venture Capital
- Wealth Management
Investment portfolio
- Alveo Technologies
Led · Series A · Jan 2018
Alveo Technologies is a San Francisco-based company that makes affordable and accessible infectious disease diagnostic devices. Led by founder and CEO Ron Chiarello, PhD, the company is pre-clinical and developing a rapid diagnostic platform for infectious diseases. Alveo intends to use the recent funding to advance optimization and commercialization of its rapid diagnostic platform. The company describes its work as creating a new ecosystem for the detection of diseases. Financially, Alveo closed a $38M Series A financing to support those development and commercialization efforts.
- ContraFect
Led · Series B · Oct 2010
ContraFect focuses on discovering and developing therapeutic proteins and monoclonal antibodies, with lysin programs aimed at treating drug‑resistant bacterial infections. Its initial product candidates target antibiotic‑resistant pathogens such as MRSA and influenza, and the company is researching lysins to target Gram‑negative bacteria including Pseudomonas aeruginosa. ContraFect emphasizes targeting conserved regions of bacteria or viruses that are less prone to mutation. The company announced eligibility for up to $2.1 million in funding from CARB‑X to advance its Gram‑negative lysin program. The award is structured as $1.1 million in initial funding with up to an additional $1.0 million contingent on achievement of milestones over the next two years. The press release also includes forward‑looking statements noting risks and uncertainties related to development and future results. ContraFect develops monoclonal antibodies and lysins aimed at treating life‑threatening bacterial and viral infections. Its lysin programs target drug‑resistant gram‑positive bacteria, including MRSA, streptococcus, and intestinal infections. The company is pursuing a shift from conventional monotherapy to combinatorial multi‑therapy using antibody and lysin combinations. Recent financings will be used to fund research and development and to advance the company's first products into clinical development. The company closed a $2.2M Series A and a $12M Series B to support these plans. Headquartered in New York, NY, ContraFect is focused on addressing growing drug resistance and therapy escape mechanisms used by pathogens.